Analysts have downgraded DOC to a HOLD rating, pointing to a history of poor capital allocation decisions that have eroded shareholder value. Since 2019, the REIT has underperformed the MSCI US REIT ETF (VNQ) by nearly 60%, and the stock currently trades at a 15–20% discount to net asset value. Attempts to stabilize funds from operations (FFO) have fallen short of guidance, with management missing its targeted growth trajectory over the past four quarters.

DOC offers a well-covered 7% dividend yield, supported by an 80% payout ratio on trailing twelve-month FFO. However, the recent strategic pivot introduces significant execution risk: senior housing assets will be spun off into Janus Living, which will be externally managed and overseen by a dual-CEO structure. Investors worry that this complex governance arrangement could slow decision-making and complicate cash flow visibility.

In the fourth quarter, DOC reported FFO per share of $0.47, slightly ahead of consensus estimates of $0.46 and up from $0.46 a year ago. Same-store net operating income rose 2.1% year-over-year, driven by a 3.4% increase in healthcare lease renewals and a 1.8% uptick in life sciences occupancy. Total revenue grew 1.9% to $433 million, reflecting higher rates in key markets but offset by slower rent escalations in select senior housing properties.

Management has outlined a multi-year plan to divest non-core assets and redeploy capital into core life sciences and medical office portfolios, targeting $600 million in dispositions by mid-2025. The spin-off of Janus Living is expected to free up $300 million in internal resources, but execution milestones hinge on securing external management contracts and finalizing leadership roles. Analysts emphasize that achieving a sustainable 4–6% FFO growth rate will require flawless execution of these strategic initiatives.